Key Points Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock. The pharmaceutical company's management is taking active steps to counter some longstanding headwinds. This is a great stock for income-focused investors, but it's also appealing to growth-minded investors. 10 stocks we like better than Bristol Myers Squibb › With a forward yield nearing 4%, Bristol Myers Squibb (NYSE: BMY) may seem like a great income buy among pharmaceutical stocks. Alongside a moderately high yield, this healthcare stock also has a nearly 20-year dividend growth track record, and trades at a low valuation.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.